Mass Tort and MDL Toolkit: From JPML Petition to Settlement Administration

Summary. This toolkit supplies the working documents of mass tort practice: a JPML motion outline for both sides, a leadership application framework, a common benefit time protocol, an index of the case management orders every MDL produces, an intake vetting screen and records request letter, fact sheet and deficiency guidance, a general causation brief outline, a bellwether selection protocol, settlement matrix design considerations, and the aggregate settlement disclosure letter and individual informed consent form that Rule 1.8(g) requires.

What this toolkit is for, and who should use it

Three facts organize mass tort work. The case management orders are the procedural law, and a lawyer who has not read all of them is operating blind. Product identification and a qualifying injury decide whether an inventory survives, and both are cheaper to establish at intake than to litigate later. And the aggregate settlement rule requires individual, informed, signed consent from every client, which is a capacity problem that must be planned for years in advance.

Use with the MDL Case Management and Bellwether Checklist.

Roadmap at a glance

1. The JPML stage.
2. Leadership and common benefit.
3. The CMO index.
4. Intake vetting and records.
5. Fact sheets and deficiencies.
6. General causation.
7. Bellwethers.
8. Settlement design.
9. Disclosure and consent.
10. Liens and distribution.

Stage 1 — The JPML motion outline

Moving for centralization:

I. The actions. Number pending, districts, filing pace, anticipated filings. Attach the schedule of actions and the complaints. II. Common questions of fact. Design and manufacture; testing; corporate knowledge of risk and when it arose; the adequacy of warnings; marketing and promotion; general causation. State each as a factual question, not a legal theory. III. Convenience and efficiency. Duplicative corporate discovery; the same custodians and documents in every case; the risk of inconsistent rulings on privilege, protective orders, and expert admissibility; the burden on multiple courts. IV. Why informal coordination is insufficient. Number of firms and districts involved; failed attempts at coordination. V. The proposed transferee district and judge. Concentration of actions; location of the defendant, documents, and witnesses; the judge's complex litigation experience; docket statistics; accessibility.

Opposing centralization:

I. Too few actions, or a manageable number in a small number of districts. II. The actions differ materially — different products, formulations, time periods, defendants, or regulatory regimes. III. Individual issues predominate even pretrial — exposure, medical history, specific causation, and prescriber decisions. IV. Voluntary coordination is working — describe the cooperation already occurring. V. Prejudice — an action near trial would be delayed. VI. Alternatively, a different district, with reasons.

Practice notes. Briefs are short and argument is a few minutes; lead with the two strongest points. A conditional transfer order for a tag-along becomes effective unless opposed within a short window — calendar it. Grounds to vacate a CTO are that the case lacks the common questions or that transfer would prejudice an imminent trial.

Stage 2 — Leadership application and common benefit protocol

Application framework:

1. Experience. Each comparable MDL, the role held, the transferee judge, and the outcome. Be specific; general claims of experience are discounted. 2. Inventory. Number of cases, how developed, and the vetting standard applied. 3. Resources. Lawyers and staff dedicated; capital available for common expenses over five to seven years; document review and expert budgets the firm can carry. 4. Cooperation. Prior service on committees; references from co-counsel and adversaries. 5. Proposed contribution. A specific role — science, corporate discovery, briefing, bellwether trials, state coordination, settlement — rather than a general offer. 6. Commitment. Agreement to be bound by the common benefit protocol and any court-imposed fee cap.

Common benefit time protocol — what a compliant submission looks like:

Rules. Record contemporaneously, in the required format. Submit every period, on time. Never submit intake, individual records, or client communication as common benefit. Expect an audit by a special master and be able to substantiate every entry.

Stage 3 — The case management order index

Every MDL produces these; build the index and read them in order.

Stage 4 — Intake vetting screen and records request

The four-screen intake form:

A case failing screen 1 or 2 should not be filed. Close it in writing, advise on the limitations consequences, and recommend prompt consultation with other counsel.

Records request letter:

[Provider], Attn: Medical Records RE: [Patient], DOB [___] — Request for Complete Records

Enclosed is a signed authorization complying with HIPAA and with the protocol entered in [MDL name and number]. Please provide the complete record for [date range], including: all office and progress notes; all operative and procedure reports; all implant, device, or product identification records including manufacturer, model, lot, and serial number; all imaging reports; all pathology; all laboratory results; all medication and prescription records; all referrals and consultation reports; and all billing records with CPT codes.

If any records exist only in an archived or prior system, please so state. Please advise of any fee before processing. If you are unable to produce within thirty days, please advise so that a subpoena may issue.

The bolded sentence is the one that matters. Product identification is the most common fatal gap, and it lives in operative reports, implant logs, and pharmacy dispensing records rather than in the narrative chart.

Stage 5 — Fact sheets and deficiency responses

Standard fact sheet fields — assemble these before the deadline, not after:

• Identifying information and case caption
• Product identification with the supporting document attached
• Dates and duration of use, exposure, or implantation
• Prescribing or implanting provider
• Injury, diagnosis date, and diagnosing provider
• All treating providers with date ranges
• Prior and subsequent medical history, including the covered condition
• Other potential causes
• Employment and lost income
• Damages claimed
• Prior claims and litigation
• Signed authorizations in the required form

Deficiency response template:

RE: Deficiency Notice dated [date] — [Plaintiff], Case No. [___]

Plaintiff responds as follows to each identified deficiency:

Deficiency 1 — [quote it]. Cured. See the amended fact sheet, Section [], and the attached [document], produced herewith as [Bates range]. Deficiency 2 — [quote it]. The requested record was requested from [provider] on [date] and again on [date]; a subpoena issued on [date]. Attached is the request correspondence. Plaintiff will supplement within [] days. Deficiency 3 — [quote it]. Plaintiff has no responsive information. [Explain why — e.g., the provider has confirmed the records were destroyed under its retention schedule; correspondence attached.]

Plaintiff requests that the deficiency be deemed cured.

Rules. Respond within the cure window, address each item separately and by number, attach proof of every effort, and never leave an item unaddressed. Unresolved deficiencies produce show-cause orders and dismissals, and reinstatement is discretionary.

Stage 6 — General causation brief outline

I. The question presented. Can [substance/product] cause [disease] in humans at [exposure levels]? II. The expert and the methodology. Qualifications; the methodology; whether it predates the litigation. III. The epidemiology. Each study: design, population, power, effect size, confidence interval, confounders addressed, and limitations acknowledged. Address the studies that cut the other way rather than omitting them. IV. Dose-response. V. Mechanism and biological plausibility. VI. Animal and in vitro evidence, with the basis for extrapolation stated. VII. Bradford Hill, applied consideration by consideration. VIII. Regulatory history — relevant and not dispositive. IX. Rule 702 analysis. Sufficient facts or data; reliable principles and methods; reliable application to the facts, established by a preponderance of the evidence under the 2023 amendment. X. Conclusion.

For the defense, the same outline inverted, with the additional themes of litigation-driven methodology, selective reliance, unaddressed confounding, unjustified extrapolation, and relative risk below the threshold the jurisdiction requires for individual inference.

Science day materials: a written primer, a glossary, a chronology of the scientific literature, and a short slide set. No advocacy, no ruling requested. The side that teaches more clearly starts ahead in every ruling that follows.

Stage 7 — Bellwether selection protocol

Elements to negotiate into the order:

The Lexecon waiver decision. Waiving gives you a judge who knows the science and a faster path to trial; declining sends the case to the transferor court with its own jury pool and its own circuit law on expert admissibility. Decide case by case, not as a policy.

Stage 8 — Settlement matrix design

Point or tier factors that appear in most matrices:

• Injury category and severity
• Revision, explant, or corrective surgery
• Duration of use, exposure, or implantation
• Age at injury
• Comorbidities and alternative causes
• Strength of product identification
• Documented treatment and hospitalization
• Death and survival claims
• Derivative claims (consortium)
• Litigation posture (filed, unfiled, in a bellwether pool)

Structural terms to negotiate carefully:

Note the structural asymmetry. Unlike a class settlement, an MDL aggregate settlement is not reviewed for fairness under Fed. R. Civ. P. 23(e). The protection for individual claimants is individual consent — which is why the next stage is not a formality.

Stage 9 — Aggregate settlement disclosure and consent

Model Rule 1.8(g) requires informed consent in a writing signed by the client, after disclosure of the existence and nature of all the claims involved and of the participation of each person in the settlement.

The disclosure letter:

Dear [Client]:

A settlement has been reached in [MDL name and number] covering all clients of this firm with claims in this litigation. Before you decide whether to participate, the rules of professional conduct require that I disclose the following, and that you make this decision individually.

1. The total settlement. $[amount], covering approximately [number] claimants represented by many law firms. 2. How awards are determined. A matrix assigns points for [factors]. The matrix is enclosed in full. 3. My firm's clients. This firm represents [number] clients participating in this settlement. Their awards range from approximately $[low] to $[high], distributed as follows: [tier distribution]. Enclosed is a schedule showing each client's tier and gross award by client number. 4. Your award. You are assigned Tier [__] based on [findings], for a gross award of $[amount]. 5. What comes out of it.

• Common benefit assessment ([__]%): $[amount]
• Attorney's fee ([__]%, as capped by the Court): $[amount]
• Case costs (itemized, enclosed): $[amount]
• Estimated lien repayment: $[amount] (Medicare $[], health plan $[], provider $[__])
• Estimated net to you: $[amount] 6. Participation threshold. The settlement takes effect only if at least [__]% of eligible claimants participate. [Defendant] may withdraw if that threshold is not met. 7. What you give up. By participating, you release [scope]. Your case will be dismissed with prejudice. 8. If you decline. Your case continues. It may be remanded to [district] for trial. I will continue to represent you. There is no assurance you will recover more, or anything, and it may take several additional years. 9. Your decision. This is your decision alone. I am available to discuss it, and you may seek independent advice about it at any time.

Please return the enclosed consent form by [date].

The consent form:

INFORMED CONSENT TO AGGREGATE SETTLEMENT

I, [name], have received and read the disclosure letter dated [date] and the enclosed settlement matrix and client award schedule. I understand: the total amount of the settlement; the number of claimants participating; the awards being made to other clients of this firm; my own award and each deduction from it; the participation threshold; the claims I am releasing; and that if I decline, my case continues.

I have had the opportunity to ask questions and to seek independent advice.

☐ I accept the settlement offer of $[gross] and authorize my attorney to execute the settlement documents on my behalf. ☐ I decline the settlement offer and wish to continue my case.

Signature: ______________________ Date: __________

Do not shortcut this. It is the most frequently disciplined failure in mass tort practice, and the documentation is what protects both the client and the lawyer.

Stage 10 — Lien resolution and the closing statement

Workflow: identify at intake → notify each lienholder of the claim → obtain a conditional payment or itemization → audit for unrelated charges → negotiate the reduction → confirm the final figure in writing → pay from the settlement fund → obtain a release of lien.

Authorities: Medicare at 42 U.S.C. § 1395y(b); Medicaid under Ahlborn, Wos, and Gallardo; ERISA plans under McCutchen and Montanile.

The client closing statement:

Provide it with the check, in writing, itemized. Every reduction obtained should be shown, because the lien negotiation is frequently the largest single contribution counsel makes to a client's net recovery.

Budget, timing, and the questions clients ask

Timing. Four to eight years from centralization to distribution. Administration alone routinely takes twelve to thirty-six months after the settlement is announced.

Cost. Leadership commitments run into the millions per firm, unreimbursed for years. Individual counsel's costs are dominated by records collection and staff time.

"Will my case be tried?" Almost certainly not. A handful of bellwethers out of thousands.

"Why is a percentage taken for lawyers I never hired?" The common benefit assessment funds the discovery and expert work that made any recovery possible. The court sets it.

"Can I say no?" Yes. That is the rule. Your case continues, and it may take years more.

Master resource index

Articles

• Multidistrict Litigation and Mass Torts
• Class Actions Under Rule 23
• Product Liability for Manufacturers, Distributors, and Sellers
• Car Accident and Personal Injury Claims
• Expert Witnesses After the 2023 Amendment to Rule 702

Guides

• Practicing in an MDL
• Handling a Product Recall
• Third-Party Litigation Funding

Checklists

• MDL Case Management and Bellwether Checklist
• Expert Disclosure and Daubert Challenge Checklist
• Personal Injury Claim Intake and Evaluation Checklist
• Product Recall Readiness Checklist

Related toolkits

• Class Action Defense Toolkit
• Personal Injury Claim Toolkit
• Expert Witness Toolkit
• Federal Civil Litigation Toolkit
• Product Safety and Recall Toolkit

Primary sources

• 28 U.S.C. § 1407 · § 1404 · § 1291 · § 1332
• Lexecon · Gelboim · Amchem · Ortiz · Bristol-Myers Squibb · Daubert
• Fed. R. Civ. P. 16 · 23 · 26 · 42 · Fed. R. Evid. 702
• 42 U.S.C. § 1395y(b) · 11 U.S.C. § 362
• ABA Model Rule 1.8(g); the Manual for Complex Litigation (Fourth); the JPML Rules of Procedure.

This toolkit is educational and not legal advice. Templates must be adapted to the case management orders of the specific MDL and to the ethical rules of the applicable jurisdiction.